Research in Social and Administrative Pharmacy
Volume 1, Issue 4 , Pages 579-598 , December 2005

Use of health-related quality of life information in managed care formulary decision-making

  • Wenchen Kenneth Wu, R.Ph., M.B.A., Ph.D.

      Affiliations

    • College of Pharmacy and Allied Health Professions, St John's University, 8000 Utopia Parkway, Jamaica, NY 11439, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 718 990 5690; fax: +1 718 990 6316.
    • ,
  • Robert B. Sause, R.Ph., Ph.D.

      Affiliations

    • College of Pharmacy and Allied Health Professions, St John's University, 8000 Utopia Parkway, Jamaica, NY 11439, USA
    • ,
  • Christopher Zacker, R.Ph., M.B.A., Ph.D.

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA

References 

  1. Kozma CM, Reeder CE, Shulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993;15:1121–1132
  2. Adams D, Wilson AL. Drug selection for safety-net-provider formularies. AJHP. 2002;59:1675–1678
  3. Goldberg R. Managing the pharmacy benefit: the formulary system. J Manag Care Pharm. 1997;3:565–573
  4. Crawford B, Dukes E, Bailey L, Evan C. The value of providing quality of life information to managed care decision makers. Drug Benefit Trends. 2001;13:45–52
  5. Campbell G, Sprague KL. The state of drug decision-making: report on a survey of P&T committee structure and practices. Formulary. 2001;36:644–655
  6. Lubeck D. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care (USA). 2002;8:811–820
  7. Testa M, Simonson D. Assessment of quality of life outcomes. N Engl J Med. 1996;331:835–839
  8. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027–3034
  9. Bukstein D. Incorporating QOL data into managed care formulary decisions: a case study with salmeterol. Am J Manag Care. 1997;3:1701–1706
  10. Wood S. Strategies for improving health plan member retention. Healthcare Financial Management 1999 HFM Resource Guide. 1999;1–5
  11. Lyles A, Luce BR, Rentz M. Managed care pharmacy, socioeconomic assessment and drug adoption decisions. Soc Sci Med. 1997;45:511–521
  12. Health Economics Leaders Study. San Francisco: The Zitter Group; 1999;
  13. Motheral BR, Grizzle AJ, Armstrong EP, Cox E, Fairman K. Role of pharmacoeconomics on drug decision-making: results of a survey. Formulary. 2000;35:412–421
  14. Lewis BE, Fish L. Formulary decisions in managed care: the role of quality of life. Drug Benefit Trends. 1997;9:41–47
  15. Sarpong D. Application of pharmacoeconomics and outcomes research in formulary decision-making. Drug Benefit Trends. 1999;11:53–57
  16. Evans C, Dukes EM, Crawford B. The role of pharmacoeconomic information in the formulary decision-making process. J Manag Care Pharm. 2000;6:108–121
  17. Johnson JA, Frieesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decision. Pharmacoeconomics. 1998;13:479–485
  18. Smith ND. Quality of life studies from the representative of an FDA reviewing statistician. Drug Information J. 1993;27:617–623
  19. Badia X, Herdman M. The importance of health-related quality-of-life data in determining the value of drug therapy. Clin Ther. 2001;23:168–174
  20. Lewis C. Grappling with the quality of life: patients, FDA and drug companies struggle to link therapies with well-being. FDA Consumer Magazine, March-April 2001. <http://fda.gov/fdac/features/2001/201_life.html>. Accessed 20.10.04.
  21. Murawski MM, Mychaskiw MA, Surdej J. Exploration of the relationship between health-related quality of life and price of pharmaceutical products. Drug Information J. 2003;37:221–231
  22. Revicki DA, Osobo D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887–900
  23. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decision. Soc Sci Med. 1997;45:535–544
  24. Who's Who in Managed Care Pharmacy. Alexandria, VA, Academy of Managed Care Pharmacy; 1999;
  25. Dillon W, Madden TJ, Firtle NE. Marketing research in a marketing environment. Burr Ridge, Ill: Irwin, Inc; 1994;
  26. Solari A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual Life Outcomes. 2005;3:16
  27. Marquis P, Chassany O, Abetz L. A comprehensive strategy for the interpretation of quality of life data based on existing methods. Value Health. 2004;7:93–104
  28. Norquist JM, Girman CJ, Santanello NC. Some considerations for the interpretation of health-related quality of life data. Value Health. 2005;8:80–81
  29. Board approves format for formulary submissions. J Manag Care Pharm. 2001;7:79
  30. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Affairs. 2004;23:124–134
  31. Fisfer VS. Clinical monograph for drug formulary: systemic agents for psoriasis/psoriatic arthritis. J Manag Care Pharm. 2005;11:33–55
  32. Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm. 2005;11:151–171
  33. Chang J, Sung J. Health plan budget impact analysis for Pimecrolimus. J Manag Care Pharm. 2005;11:66–73

PII: S1551-7411(05)00098-7

doi: 10.1016/j.sapharm.2005.09.004

Research in Social and Administrative Pharmacy
Volume 1, Issue 4 , Pages 579-598 , December 2005

Article Tools

* Image Usage & Resolution